SYRE
Aeglea BioTherapeutics Inc

2,045
Mkt Cap
$1.75B
Volume
569,245.00
52W High
$40.26
52W Low
$10.91
PE Ratio
-10.34
SYRE Fundamentals
Price
$22.52
Prev Close
$22.39
Open
$21.88
50D MA
$19.01
Beta
0.83
Avg. Volume
1.26M
EPS (Annual)
-$3.18
P/B
3.01
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
FY2025 Earnings Estimate for SYRE Issued By Leerink Partnrs
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Leerink Partnrs increased their FY2025 EPS estimates for Spyre Therapeutics in a research note issued on Tuesday, November 4th. Leerink Partnrs...
MarketBeat·24h ago
News Placeholder
More News
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Spyre Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 45,000 Shares
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 45,000 shares of the business's stock in a transaction that occurred on Monday, November 3rd. The shares were sold at...
MarketBeat·2d ago
News Placeholder
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
Zacks·5mo ago
News Placeholder
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
Zacks·6mo ago
News Placeholder
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics to Participate in Upcoming March Investor Conferences Spyre Therapeutics to Participate in Upcoming March Investor Conferences PR Newswire WALTHAM, Mass., Feb. 25, 2025 WALTHAM...
PR Newswire·9mo ago
News Placeholder
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the...
PR Newswire·9mo ago
News Placeholder
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Feb. 7, 2025 WALTHAM, Mass., Feb. 7, 2025 /PRNewswire...
PR Newswire·9mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre...
PR Newswire·9mo ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·9mo ago

Latest SYRE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.